Select your timezone:

Mon
Apr 24 Tue
Apr 25

Time	Room	Session
08:30 09:45	08:30-09:45	Riverfront	Immunoprotection of Stem Cell Islets: Genome Editing and Beyond Full Details Holger Russ, United States Hypoimmunogenic stem cell islets Holger Russ, United States Hypoimmunogenic stem cell islets Lorenzo Piemonti, Italy Protection from NK mediated damage Lorenzo Piemonti, Italy Protection from NK mediated damage Elad Sintov, United States CRISPR screening to attain immunoprotection of stem cell-derived islets Elad Sintov, United States CRISPR screening to attain immunoprotection of stem cell-derived islets Haval Shirwan, United States Microgels presenting FasL as an immunomodulatory scheme to protect beta cells from rejection Haval Shirwan, United States Microgels presenting FasL as an immunomodulatory scheme to protect beta cells from rejection Jeffrey Millman, United States Panel Discussion and Q&A Jeffrey Millman, United States Panel Discussion and Q&A
09:45 - 10:15 \| Networking Coffee Break. Parkview & Somerset
10:15 11:30	10:15-11:30	Riverfront	The Islet Product, Planning for Trials, and Manufacturing Full Details Yasaman Aghazadeh, Canada Recapitulating the vascular niche to improve beta cell replacement therapies for T1D Yasaman Aghazadeh, Canada Recapitulating the vascular niche to improve beta cell replacement therapies for T1D William Rust, United States Stem cell-derived islets for treating diabetes: The Seraxis approach William Rust, United States Stem cell-derived islets for treating diabetes: The Seraxis approach Jerome Ritz, United States Planning for clinical trials: Lessons learned from autologous iPSC-derived products Jerome Ritz, United States Planning for clinical trials: Lessons learned from autologous iPSC-derived products Tom Bollenbach, United States Scale - up manufacturing; how to do it or not so easy? Tom Bollenbach, United States Scale - up manufacturing; how to do it or not so easy? James Markmann, United States Panel Discussion and Q&A James Markmann, United States Panel Discussion and Q&A
11:30 - 11:45 \| Break Parkview & Somerset
11:45 12:30	11:45-12:30	Riverfront	Panel Discussion: Eligibility Criteria Considerations for Stem Cell Trials in Diabetes Full Details Patricia Beaston, United States Panelist Patricia Beaston, United States Panelist Yohannes Haile, Canada Panelist Yohannes Haile, Canada Panelist Bruce Perkins, Canada Panelist Bruce Perkins, Canada Panelist Thierry Berney, Switzerland Panelist Thierry Berney, Switzerland Panelist Michael R Rickels, United States Panelist Michael R Rickels, United States Panelist
12:30 12:45	12:30-12:45	Riverfront	Closing Remarks Full Details

Organized by

A section of

Email: info@betacells.org

514-874-1717 x203

© 2024 BetaCells 2023